Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · Psoriasis / Comorbidities Per AAD-NPF 2019/2020 + UpToDate 2024 · Updated 2026-05-09

Psoriasis comorbidities & special populations
PsA, CV, pregnancy, pediatric, nail, erythrodermic

TL;DR:Psoriasis calls for active screening for arthritis and cardiometabolic comorbidity, which feeds directly into treatment choice. About half of patients improve during pregnancy and flares are common within six weeks of delivery; childhood, nail and erythrodermic psoriasis each need their own assessment.

Psoriasis is not just a skin disease — it is systemic inflammation. AAD-NPF 2019 comorbidities guideline mandates screening for seven essentials: psoriatic arthritis (15-30%), cardiovascular disease, metabolic syndrome, T2DM, NAFLD, depression/anxiety/suicidality, IBD. Special populations covered: pregnancy/lactation (certolizumab safest), pediatric (ustekinumab/secukinumab/ixekizumab approved ≥ 6 y), nail psoriasis, erythrodermic emergency (cyclosporine/infliximab first-line).

Note: Comorbidity screening and special-population management cross multiple specialties (rheumatology, cardiology, hepatology, endocrinology, psychiatry, OB/GYN, pediatrics). Individualized care required. Patient education only.
Key Fact (Elmets 2019, JAAD · Menter 2020, JAAD pediatric)

10-year CV event risk is elevated in moderate-severe psoriasis, equivalent to the level seen in diabetic patients (Mehta 2010, Am J Med）。Psoriatic arthritis (PsA), if undiagnosed in time, — within 5 years can cause irreversible joint destruction and impair function. AAD recommends that all psoriasis patients should "Ask about joint symptoms annually" + "routine cardiovascular / metabolic / mood screening".Pregnancy: 50% of psoriasis patients improve spontaneously during pregnancy; postpartum flare is common — drug selection requires special care.

Seven essential comorbidity screens

  • Psoriatic arthritis (PsA) — 15–30% prevalence; PEST screen yearly; refer to rheumatology if morning stiffness > 30 min, dactylitis, enthesitis, or DIP arthritis.
  • Cardiovascular disease — MI/stroke risk ↑ 1.4–3×; annual BP, BMI, waist, fasting glucose, lipid panel; treat ASCVD risk like a diabetic.
  • Metabolic syndrome / obesity / T2DM — OR 1.5–2×; 5–10% weight loss improves PASI by ≥ 50%.
  • NAFLD / MASLD — prevalence ~47% in psoriasis; rule out before MTX; biologics safer.
  • Depression / anxiety / suicidality — yearly PHQ-2; brodalumab carries suicidality warning.
  • IBD — Crohn OR 2.5, UC 1.7; IL-17 inhibitors may worsen IBD; prefer TNFi or IL-23i (guselkumab/risankizumab also treat IBD).
  • Uveitis, lymphoma (slight ↑ SIR), CKD.

Pregnancy

50% improve, 25% unchanged, 25% worsen; 60% postpartum flare. Safe: low-mid potency topical steroids (limited area), NB-UVB (with folate), certolizumab pegol (no transplacental due to no Fc). Avoid: methotrexate (3-month wash-out), acitretin (3-year wash-out), PUVA, tazarotene. Acute generalized pustular psoriasis of pregnancy (impetigo herpetiformis): cyclosporine + systemic steroid + admission; spesolimab (anti-IL-36R) approved for GPP.

Pediatric psoriasis

Prevalence ~1%; 1/3 onset before 18; guttate (post-strep) and plaque most common. Topicals first-line. Approved pediatric biologics: etanercept ≥ 4 y, ustekinumab ≥ 6 y, ixekizumab ≥ 6 y, secukinumab ≥ 6 y (BAD 2023 expansion), adalimumab ≥ 4 y (region-dependent). Avoid PUVA in young children. Screen comorbidities (BMI, BP, PsA, mood) like adults.

Nail psoriasis

50% of skin psoriasis; matrix signs (pitting, leukonychia, red lunula, crumbling) and bed signs (oil-drop, onycholysis, subungual hyperkeratosis, splinter hemorrhage). Mild: topical calcipotriol/tazarotene to nail folds. Moderate: intralesional triamcinolone every 4–8 weeks. Severe (multi-digit, high QoL impact): systemic — IL-17i (ixekizumab), IL-23i (risankizumab), TNFi (adalimumab, infliximab) reach 50–70% NAPSI clearance.

Erythrodermic psoriasis — emergency

> 90% BSA erythema with scale; mortality 4–64%. Triggers: abrupt steroid withdrawal, infection, lithium, antimalarials. Admit; monitor temp, fluids, electrolytes, albumin; bland topicals + low-potency steroid + wet wraps. First-line systemic: cyclosporine (2–5 mg/kg/day) or infliximab (rapid onset). Transition to maintenance IL-17i/IL-23i/ustekinumab. Avoid slow-onset agents (MTX, acitretin) in the acute phase.

Bottom line

Psoriasis is systemic. Annual comorbidity screening (joints, BP, glucose, lipids, mood, DLQI) reduces long-term cardiovascular, disability, and suicide risk. Pregnancy, pediatric, nail, and erythrodermic disease all have evidence-based protocols — don't dismiss psoriasis as "just skin".